New Zealand markets close in 6 minutes

Merck & Co., Inc. (MRK)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
81.17+0.10 (+0.12%)
At close: 4:02PM EDT
81.00 -0.17 (-0.21%)
After hours: 07:59PM EDT

Merck & Co., Inc.

2000 Galloping Hill Road
Kenilworth, NJ 07033
United States
908 740 4000
http://www.merck.com

Sector(s)Healthcare
IndustryDrug Manufacturers—General
Full-time employees73,000

Key executives

NameTitlePayExercisedYear born
Mr. Kenneth C. FrazierExec. Chairman4.3MN/A1955
Mr. Robert M. DavisPres, CEO & Director2.29M6.62M1967
Ms. Jennifer L. ZacharyExec. VP, Gen. Counsel & Corp. Sec.1.79MN/A1978
Mr. Sanat ChattopadhyayExec. VP & Pres of Merck Manufacturing Division1.56MN/A1960
Ms. Caroline LitchfieldExec. VP & CFON/AN/AN/A
Mr. David Michael WilliamsChief Information & Digital OfficerN/AN/AN/A
Mr. Peter DannenbaumVP of Investor RelationsN/AN/AN/A
Michael W. FlemingSr. VP and Chief Ethics & Compliance OfficerN/AN/A1959
Ms. Jennifer MauerVP of Global CommunicationsN/AN/AN/A
Ms. Cristal N. DowningExec. VP and Chief Communications & Public Affairs OfficerN/AN/AN/A
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaboration agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; Amathus Therapeutics to develop treatments for neurodegenerative diseases; and Linnaeus Therapeutics, Inc. to evaluate LNS8801. It also has a collaboration with Biomed X Gmbh for building on ongoing research projects in the fields of oncology and autoimmunity (intestinal epithelial barrier in autoimmune diseases); NGM Biopharmaceuticals, Inc. to focus primarily on the development of medicines in retinal and CVM diseases; and to develop and commercialize tests that identify genetic mutations, as well as with IO Biotech ApS to evaluate IO102-IO103. It also has a partnership with Biocorp Production for the development and supply of a specific version of Mallya device. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Corporate governance

Merck & Co., Inc.’s ISS governance QualityScore as of 26 September 2021 is 3. The pillar scores are Audit: 9; Board: 8; Shareholder rights: 2; Compensation: 1.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.